Arginine silicate

Arginine Silicate (Inositol-Stabilized Arginine Silicate)

1. Identity, Chemistry, and Composition

Arginine silicate is a synthesized ionic complex formed by bonding the semi-essential amino acid L-arginine with orthosilicic acid (a bioavailable form of silicon). Its most commercially prominent form is inositol-stabilized arginine silicate (ASI), in which a bonded arginine–silicate complex is further stabilized by the addition of inositol; this formulation is a novel bioavailable source of arginine, silicon, and inositol providing multiple health benefits. In the United States it is affirmed as generally recognized as safe (GRAS) and is marketed after FDA New Dietary Ingredient Notification under the tradename Nitrosigine®.

The arginine silicate inositol complex (ASI) has a reported compositional profile of approximately arginine 49.5%, silicon 8.2%, and inositol 25%, making it a novel, bioavailable source of silicon and arginine. In vitro dissociation data demonstrate that the arginine silicate component of ASI dissociates upon ingestion in the acidic environment of the stomach, liberating its individual components for absorption. Arginine silicate is highly soluble in water and provides good nutritional availability of both arginine and silicate.

Arginine silicate may be used both as a source of the essential amino acid arginine and as a source of silicate, both of which exert antiatherosclerotic effects; the oral administration of this compound delivers arginine and silicate to appropriate sites of action.

Common Forms and Preparations

For oral administration, arginine silicate may be provided as a tablet, aqueous or oral suspension, dispersible powder or granule, emulsion, hard or soft capsule, syrup, or elixir. In human clinical studies, subjects have taken three 500 mg capsules (total of 1,500 mg/day) of arginine silicate (Nitrosigine®), an FDA generally recognized as safe substance. It is also formulated as stick-pack powder dissolved in water. Arginine silicate inositol is also listed as a Natural Health Product in Canada under Health Canada regulations.

2. Component Ingredients: Natural Sources and Background

L-Arginine

L-arginine is a conditionally essential amino acid found naturally in protein-rich foods including meat, poultry, fish, dairy, nuts, and legumes. Nitric oxide (NO) serves as a critical mediator of vascular function, contributing to vasodilation, the regulation of blood flow, and the prevention of thrombosis; as a primary precursor of NO, L-arginine is essential for maintaining endothelial integrity, modulating mitochondrial function, and reducing oxidative damage. Endothelial nitric oxide synthase (eNOS) utilizes L-arginine as the principal substrate, converting it to L-citrulline and nitric oxide.

Silicon (as Orthosilicic Acid)

Silicon (Si) is the most abundant element present in the Earth's crust besides oxygen. Silicon is an abundant trace element found in many plant-based foods as well as many antacids and analgesics. Dietary silicon is consumed primarily through plant foods such as whole grains, vegetables, and beverages such as beer; its bioavailability depends heavily on the specific compound. Silicon has been associated with bone mineralization, collagen synthesis, skin, hair and nail health, atherosclerosis, Alzheimer's disease, and immune system enhancement.

Inositol

Inositol (specifically myo-inositol) is a naturally occurring polyol found in grains, legumes, fruits, and meats. In the ASI complex, its role is structural: ASI is formulated as a unique complex that binds arginine with silicon, a nutrient that appears to enhance the bioavailability of L-arginine and may support the strength and flexibility of arterial walls; the stabilization with inositol, along with arginase inhibition, underlies the greater bioavailability of ASI.

3. Historical and Traditional Context

Arginine silicate as a discrete chemical entity or supplement has no documented traditional or historical use in any pre-modern culture, pharmacopeia, or herbal tradition. It is an entirely novel synthesized compound, first described in patents filed in the mid-1990s and subsequently investigated scientifically. The utility of arginine silicate as a therapeutic or preventative agent for atherosclerosis, and its potential as a dietary supplement to maintain an antiatherogenic state, was first articulated in its foundational patent documentation.

However, the two individual constituents—L-arginine and silicon—each carry independent histories of scientific and nutritional interest. L-arginine has been studied as a cardiovascular supplement since the 1980s, following the discovery of nitric oxide's role in endothelial function (a finding honored with the 1998 Nobel Prize in Physiology or Medicine). Silicon, meanwhile, was identified as a potentially essential dietary trace element for connective tissue and bone formation in animal studies beginning in the 1970s. The impact of dietary silicon appears to be a positive effect on connective tissue growth and maintenance; the earliest studies of Carlisle and Schwarz showed dramatic detrimental changes in the structure of bone and collagenous tissues — such as skull deformities in rats and absent wattles and combs in chicks — when dietary silicon deprivation was induced.

4. Active Constituents and Established Mechanisms of Action

Nitric Oxide (NO) Pathway via L-Arginine

The central proposed mechanism of arginine silicate involves elevation of plasma L-arginine, which feeds the enzymatic production of NO via endothelial nitric oxide synthase. In the NOS-dependent mechanism, NO is produced from L-arginine and oxygen by enzymatic reactions catalysed by NOS isoforms, such as endothelial nitric oxide synthase (eNOS). eNOS is predominantly found in endothelial cells, where it regulates vascular tone and blood flow by producing NO in response to such stimuli as shear stress and acetylcholine.

The endothelial production of nitric oxide (NO) mediates endothelium-dependent vasorelaxation and restrains vascular inflammation, smooth muscle cell proliferation, and platelet aggregation. Reduced access to L-arginine has been proposed as a major mechanism underlying reduced eNOS activity and NO production in cardiovascular disease; the arginases (Arg1 and Arg2) metabolize L-arginine to generate L-ornithine and urea, and increased expression of arginase has been proposed as a mechanism of reduced eNOS activity secondary to the depletion of L-arginine.

A key proposed advantage of the arginine silicate complex over free L-arginine is improved bioavailability. There is limited evidence to support the efficacy of supplemental L-arginine alone in cardiovascular disease, and results are more promising when L-arginine is combined with other substances, such as silicon, that enhance absorption and bioavailability. A study in rat models demonstrated that arginine silicate inositol complex is more effective in increasing serum arginine levels than the commonly used arginine hydrochloride product.

Role of Silicon in Vascular and Bone Biology

Silicon plays an important role in skin and bone health, and there is some evidence to suggest that silicon, especially as silicic acid, may protect vascular integrity during age-related vascular diseases. Bone matrix is predominantly made up of collagen, and in vitro and animal model studies have shown that silicon is linked to glycosaminoglycans and plays an important role in the formation of cross-links between collagen and proteoglycans, determining beneficial effects on strength, composition, and mechanical properties of bone.

Evidence from human, animal, and in vitro studies indicates that silicon in nutritional and supra-nutritional amounts promotes bone and connective tissue health, may have a modulating effect on the immune or inflammatory response, and has been associated with mental health; a plausible mechanism of action for the beneficial effects of silicon is the binding of hydroxyl groups of polyols such that it influences the formation and/or utilization of glycosaminoglycans, mucopolysaccharides, and collagen in connective tissue and bone.

It has been demonstrated that silicon enhances prolyl hydroxylase activity, stabilizes collagen cross-linking, and increases bone matrix mineralisation in vitro. In vitro studies have shown that silicon stimulates the synthesis of type I collagen and osteoblastic differentiation, as assessed by alkaline phosphatase and osteocalcin levels, in osteoblastic-like human cells.

Inositol as Stabilizer and Secondary Signaling Agent

Inositol-stabilized arginine silicate ingestion has been reported to increase nitric oxide levels, while inositol itself has been reported to enhance neurotransmission. By stabilizing the arginine–silicate bond, inositol is also thought to retard enzymatic breakdown by arginase, thereby prolonging the elevation of plasma arginine.

5. Pharmacokinetics

On Day 1, pharmacokinetic parameters for arginine after a 1,500 mg dose were: peak serum concentration (C_max) 30.06 ± 7.80 μg/mL, time to reach peak serum concentration (t_max) 1.13 ± 0.52 hours, and half-life (t_1/2) 15.93 ± 9.55 hours; for silicon, C_max was 2.99 ± 0.63 μg/mL, t_max 2.44 ± 2.05 hours, and t_1/2 34.56 ± 16.56 hours.

The arginine silicate dietary supplement increases blood levels of arginine after a single dose within 30 minutes and blood levels of silicon for up to 1.5 hours; blood levels of arginine, silicon, and NO (salivary nitrite) were elevated consistently after 14 days of use. ASI starts to work within 15 minutes of ingesting and significantly increases arginine levels for up to 6 hours.

6. Scientific Evidence by Area of Use

6.1 Nitric Oxide Production and Vascular Function

Human clinical evidence: A clinical study was conducted to characterize the pharmacokinetics and pharmacodynamics of an oral inositol-stabilized arginine silicate dietary supplement; ten healthy males aged 26.7 ± 5.4 years took three 500 mg arginine silicate capsules (total 1,500 mg/day) for 14 days. Results indicated that the arginine silicate dietary supplement increased blood levels of arginine and silicon in both an acute and chronic dosing regimen; after a single 1,500 mg dose, levels of arginine increased significantly for up to 5 hours and levels of silicon for up to 1.5 hours.

In a separate open-label proteomic study, ten healthy males received 1,500 mg ASI/day; plasma proteins were quantified by mass spectrometry-based multiple reaction monitoring, and the 6-hour post-dose analysis resulted in statistically significant changes in 73 out of 107 (68%) proteins compared to pre-dose levels. These protein changes included markers of cardiovascular and vascular function, though the clinical translation of this proteomic shift requires further study.

Vasodilation study: A study of healthy, normotensive, and physically active male (n=16) and female (n=8) young adults utilized a randomized, double-blind, within-subjects design where participants reported for three trials, each preceded by a 7-day washout period. This study evaluated flow-mediated dilation (FMD) via ultrasound as an objective measure of vasodilation.

Evidence strength: Evidence for acute elevations in plasma arginine and salivary nitrite (as a NO proxy) is consistent across multiple small studies. However, most published clinical trials to date have been small (n=10–24), short in duration, and several were funded by the ingredient manufacturer. Independent large-scale RCTs are lacking.

6.2 Athletic Performance and Muscle Recovery

Human clinical evidence: Considering ASI's unique structure and positive effects on NO production, blood flow, and arginine and silicon absorption, researchers hypothesized that intake of this complex could improve muscle recovery; the purpose of one study was to determine if ASI supplementation, in combination with exercise, can increase blood flow to working muscles and the body overall, and in turn, lead to greater muscle growth and/or recovery.

In a published study, creatine kinase (CK) levels — a biomarker of muscle damage — significantly decreased in the ASI group at 24 hours (p=0.040), 48 hours (p=0.017) and 72 hours (p=0.034) post-exercise compared to the placebo group; immediately post-exercise, ASI supplementation led to 44% less muscle damage as measured by CK levels compared to placebo (p=0.057), though this between-group difference was not statistically significant at that time point. LDH levels significantly increased from baseline immediately after exercise in the placebo group (p=0.015), but not in the ASI group (p=0.366), though between-group differences were not statistically significant.

Comparison studies have found that supplementing with inositol-stabilized arginine silicate (ASI) more efficiently elevates serum arginine and serum citrulline than standard oral L-arginine.

Evidence strength: The evidence for muscle damage attenuation is preliminary and based on small studies. The primary blood flow outcomes (femoral artery velocity) showed increases in both ASI and placebo groups post-exercise with no statistically significant between-group difference, as blood flow increased 59.9 cm/s in the ASI group (p<0.005) and 49.9 cm/s in the placebo group (p<0.005) after exercise on Day 3, with p=0.2 between groups. This limits conclusions about direct ergogenic effects on performance.

6.3 Cognitive Function

Human clinical evidence: Inositol-stabilized arginine silicate (Nitrosigine®) has been validated to increase levels of arginine, silicon, and nitric oxide production; to evaluate potential enhancement of mental focus and clarity, ASI at 1,500 mg/day was tested in two double-blind placebo-controlled crossover studies using the Trail Making Test (TMT, Parts A and B).

In the two studies, healthy males took ASI for 14 and 3 days, respectively; in the first study, after 14 days of dosing, TMT B time decreased significantly from baseline (28% improvement, p=0.045); in the second study evaluating shorter-term effects, TMT B time decreased significantly compared to placebo (33% improvement, p=0.024) in a 10-minute period; after 3 days of dosing, TMT B time significantly decreased from baseline scores (35% improvement, p<0.001); these findings show that ASI significantly improved the ability to perform complex cognitive tests requiring mental flexibility, processing speed, and executive functioning.

Nitrosigine (ASI) led to a significant decrease in TMT B time compared to placebo, with an effect size of d=0.80, showing the strength of the effect to be considerable. However, funding for these studies was provided by Nutrition 21, LLC through a restricted grant, and the arginine silicate inositol complex was provided by Nutrition 21, LLC under the trademark Nitrosigine®.

A further study examined cognitive outcomes in young adults using a broader neuropsychological battery: the purpose was to examine acute ASI effects on young healthy adults by assessing multiple cognitive domains; nineteen young adults (20.9 ± 3.2 years) completed this randomized, double-blind, crossover study consuming ASI (1.5 g ASI + 12 g dextrose) or placebo (12 g dextrose). Repeated measures ANOVA demonstrated that ASI consumption significantly improved total RBANS and immediate memory scores compared to the placebo (p<0.05). No significant differences were identified between groups for attention, processing speed, recognition memory, language, and visuospatial skills; however, a minimal clinically meaningful difference was observed for immediate memory, delayed memory, and global cognition.

A study in e-sports gamers also showed benefits: a double-blind, randomized, placebo-controlled, crossover trial examined whether acute inositol-enhanced bonded arginine silicate ingestion affects cognitive function in e-sport gamers; 26 healthy male (n=18) and female (n=8) experienced gamers (23 ± 5 years) were randomly assigned to consume 1,600 mg of ASI+I or 1,600 mg of a maltodextrin placebo. Self-reported energy levels increased, anger decreased, and TMT-B test errors decreased in the supplement group compared to placebo (p<0.05); fatigue, TMT-B time, and TMT B–A score improved in the supplement group compared to baseline (p<0.05); after 60 minutes of gaming, supplementation decreased Stroop Test errors and TMT-A time (p<0.05).

Evidence strength: Cognitive studies are consistently positive in direction, but most use small samples of healthy young males, short durations, and crossover designs. The mechanistic hypothesis—that increased cerebral blood flow mediated by NO underlies cognitive benefits—is plausible but not yet confirmed by direct imaging studies. Industry funding is a consistent limitation across the body of evidence.

6.4 Bone Health

The arginine silicate complex has been proposed to promote bone and cartilage formation; bioavailable nutritional silicon in the form of the arginine silicate complex increases bone density and prevents bone demineralization, and in one preferred embodiment the complex is administered prophylactically to prevent bone demineralization and cartilage degradation. These claims originate from patent literature; the following describes peer-reviewed studies.

Animal studies: In quail subjected to heat stress, serum osteocalcin, dehydroepiandrosterone concentrations, and alkaline phosphatase activity increased, whereas tumor necrosis factor-alpha and C-reactive protein concentrations decreased, as dietary ASI supplementation increased; this improvement was linear with increased supplement dose (p=0.001); the amount of Ca, P, Mg, and Mn in the excreta decreased and concentrations of these minerals in tibia ash increased in quail reared under heat stress; in conclusion, ASI supplementation to the basal diet significantly improved bone mineralization in quail.

In a rat bone healing study: the study evaluated the potential effects of the ASI complex on bone healing of critical-sized defects in rats; rats were randomly assigned to two groups of 21 rats each; the control group was fed a standard diet for 12 weeks, while the ASI group was fed a diet containing 1.81 g/kg of ASI for 12 weeks; after the first 8 weeks, a calvarial critical-sized defect was created, and rats were sacrificed 7, 14, and 28 days later.

In rainbow trout, ASI supplementation at various levels (0, 500, 1,000 mg/kg) was evaluated for effects on growth, feed intake, feed conversion ratio (FCR), and concentrations of body elements; ASI supplementation significantly improved operculum bone ash and whole body mineral content and did not impact feed consumption, weight gain, or FCR.

Evidence strength: Evidence for bone health effects is largely from animal models (quail, rats, fish). There are still no precise indications regarding a possible role of silicon on bone health in humans from direct human trials of ASI specifically. Broader silicon research provides biologically plausible support, but direct human RCTs of arginine silicate for bone endpoints have not been published in the peer-reviewed literature.

6.5 Cardiovascular Markers

Arginine silicate has been proposed as a therapeutic or preventative agent for atherosclerosis and as a dietary supplement to maintain an antiatherogenic state. Preclinical evidence in animal models of insulin resistance suggests favorable vascular effects. ASI intake has been shown in clinical and preclinical studies to improve markers associated with cardiovascular health.

Vascular dysfunction and damage have been shown to be associated with impaired endothelial NO metabolism and function. Enhanced NO availability, via arginine administration, induces vasodilation, increases blood flow to the working musculature, improves cardiovascular health, lowers blood pressure, and improves exercise performance.

Evidence strength: Clinical evidence specifically for cardiovascular disease endpoints (e.g., reduction in events, plaque regression) from human trials of arginine silicate itself is absent in the published literature. There is limited evidence to support the efficacy of supplemental L-arginine alone in cardiovascular disease. The ASI complex's improved arginine bioavailability offers a theoretical advantage, but clinical cardiovascular outcome trials have not been conducted.

7. Body Systems and Health Areas

• Cardiovascular / Vascular: Via NO-mediated vasodilation, endothelial function, and arterial wall support from silicon. Nitric oxide is best known for its role in vasodilation and related cardiovascular health.
• Musculoskeletal: Silicon is linked to glycosaminoglycans and plays an important role in the formation of cross-links between collagen and proteoglycans, and bone matrix studies show silicon's role in determining strength, composition, and mechanical properties of bone.
• Neurological / Cognitive: Research demonstrates that NO may be a prospective therapeutic approach in managing mild cognitive impairment due to its mechanistic action, increasing systemic blood flow and, conceivably, cerebral circulation.
• Connective Tissue / Skin: Typical signs of aging skin include a fall in silicon and hyaluronic acid levels in connective tissues, resulting in loss of moisture and elasticity in the skin.
• Athletic / Exercise Performance: Via increased muscle blood flow, reduced exercise-induced muscle damage markers, and attenuation of post-exercise cognitive decline.

8. Dosage Forms and Reported Dosages

All dosages below are as reported in cited studies; they do not represent recommendations.

• In the primary pharmacokinetics and safety study, ten healthy males took three 500 mg arginine silicate capsules (active product) for 14 days, totaling 1,500 mg/day.
• In two double-blind placebo-controlled crossover cognitive studies, ASI was administered at 1,500 mg/day using the Trail Making Test as an assessment tool.
• In a randomized, double-blind, crossover cognitive outcomes study, participants consumed 1.5 g ASI + 12 g dextrose as a single acute dose.
• In the gamers study, participants consumed 1,600 mg of inositol-enhanced bonded arginine silicate (nooLVL®) or placebo.
• In the rat bone-healing animal study, the ASI group was fed a diet containing 1.81 g/kg of ASI for 12 weeks.
• In the rainbow trout mineral study, ASI supplementation levels of 0, 500, and 1,000 mg/kg were evaluated.

9. Safety Considerations and Interactions

Regulatory Status

ASI (Nitrosigine) has been affirmed as generally recognized as safe and is marketed in the United States after Food and Drug Administration New Dietary Ingredient Notification. Arginine silicate inositol is also listed as a Natural Health Product in Canada.

Cardiovascular Safety (Heart Rate and Blood Pressure)

Available data show that ASI intake at daily doses of 1,500 mg does not induce elevations in heart rate or blood pressure; while intake of other known energy-stimulating ingredients can increase heart rate and blood pressure even after a single dose, ASI intake did not change heart rate or blood pressure after both short-term (after 25 minutes) and longer-term (after 14 days) use. Overall, clinical and preclinical data suggest that ASI (Nitrosigine) can be safely used as a non-stimulant ingredient to increase physical energy and cognitive function without adverse cardiovascular effects.

Genotoxicity

Referenced in the pharmacokinetics study, published abstracts reported that orally administered arginine silicate inositol complex was found not to be clastogenic in Chinese hamster ovary cells (FASEB J. 2004), and was not toxic in a mouse micronucleus assay (FASEB J. 2004). These findings support basic genotoxicity safety, though they are presented only as conference abstracts.

Clinical Trial Adverse Events

In the muscle recovery study, no safety concerns were raised. In the gamers study, chi-squared analysis revealed that no significant differences were observed between treatments in perceptions of the frequency or severity of dizziness, headache, tachycardia, heart palpitations, dyspnea, nervousness, blurred vision, or other complaints; side effects reported were infrequent. In the eSports study, adverse events were minimal and not different between groups.

Clinical studies have demonstrated no adverse effects following the administration of arginine; similarly, no adverse effects were observed following the administration of inositol 12 g/day for 4 weeks or of silicon 45 mg/day for 31 days, based on prior published literature cited in safety dossiers.

Exclusion Criteria Noted in Clinical Studies

In the primary safety and pharmacokinetics trial, subjects with elevated blood pressure (≥140/90), those taking silicate supplements or medications containing silicate, those with elevated serum creatinine, or those with a significant medical history were excluded. This indicates that the available safety data apply specifically to healthy normotensive adults and may not be generalizable to populations with renal impairment or elevated blood pressure.

Funding Conflict of Interest

A significant proportion of published human clinical research on ASI has been funded in full or in part by the manufacturer Nutrition 21, LLC, as noted explicitly in multiple publications. Funding for the cognitive studies was provided by Nutrition 21, LLC through a restricted grant. The heart rate and blood pressure evaluation was also funded by Nutrition 21, LLC. Independent replication with no commercial sponsorship has been limited and should be considered when evaluating the overall evidence base.

Potential Drug Interactions

No peer-reviewed published studies specifically documenting drug-drug or drug-supplement interactions with arginine silicate as a distinct entity were identified in available sources. Based on the known pharmacology of its components: L-arginine is a precursor to NO and may theoretically potentiate the vasodilatory effects of antihypertensive medications or phosphodiesterase inhibitors. These interactions are inferred from the broader L-arginine literature and have not been specifically studied for the arginine silicate complex.

10. Limitations of the Existing Evidence Base

• The majority of published human trials involve small sample sizes (typically n=10–26).
• Study populations have been overwhelmingly young, healthy, physically active males; evidence in women, older adults, or clinical populations is very limited.
• Virtually all human trials have been of short duration (1 day to 14 days), with no long-term safety or efficacy data published in peer-reviewed form.
• Further study on the effect of this supplement on NO production and the resulting physiological effect is warranted.
• Most clinical studies have been sponsored by the ingredient manufacturer, introducing potential conflicts of interest.
• Bone health evidence for ASI in humans is absent; existing bone data derive entirely from animal and poultry models.

References

• Kalman DS et al. A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males. Clin Pharmacol. 2015;7:103–109. PMC4603712
• Komorowski J, Hewlings S. Randomized Prospective Double-Blind Studies to Evaluate the Cognitive Effects of Inositol-Stabilized Arginine Silicate in Healthy Physically Active Adults. Nutrients. 2016;8(11):736.
• Gills JL et al. Acute Inositol-Stabilized Arginine Silicate Improves Cognitive Outcomes in Healthy Adults. Nutrients. 2021;13(12):4272. PMC8703995
• Sowinski R et al. Effects of Inositol-Enhanced Bonded Arginine Silicate Ingestion on Cognitive and Executive Function in Gamers. Nutrients. 2021;13(11):3758. PMID:34836014
• Rood-Ojalvo S et al. The benefits of inositol-stabilized arginine silicate as a workout ingredient. J Int Soc Sports Nutr. 2015;12(Suppl 1):P14. PMC4595023
• Rogers JM, Gills J, Gray M. Acute effects of Nitrosigine® and citrulline malate on vasodilation in young adults. J Int Soc Sports Nutr. 2020;17(1):12.
• Yaman F et al. Dietary arginine silicate inositol complex increased bone healing: histologic and histomorphometric study. Drug Des Devel Ther. 2016;10:2081–2086. PMC4930222
• Sahin K et al. Dietary arginine silicate inositol complex improves bone mineralization in quail. Poult Sci. 2006;85(3):486–492. PMID:16553280
• Küçükbay FZ et al. Effects of dietary arginine silicate inositol complex on mineral status in rainbow trout. Aquaculture Nutrition. 2008;14(2):115–125.
• Sahin N et al. Dietary arginine silicate inositol complex improves bone mineralization in quail under heat stress. Poultry Science. 2019.
• Komorowski J et al. Arginine Silicate Supplementation Decreases Markers of Cardiovascular, Renal and Metabolic Dysfunction. FASEB J. 2015;29(S1):748.2.
• Sylla S, Ojalvo SP, Komorowski J. An Evaluation of the Effect of Inositol-Stabilized Arginine Silicate on Heart Rate and Blood Pressure. FASEB J. 2018;32:724.12.
• Jurkić LM et al. Biological and therapeutic effects of ortho-silicic acid and some ortho-silicic acid-releasing compounds: New perspectives for therapy. Nutr Metab. 2013;10:2. PMC3546016
• Fabris S et al. Silicon: A neglected micronutrient essential for bone health. Exp Biol Med. 2021;246:1748–1755. PMC8283247
• Nielsen FH. Update on the possible nutritional importance of silicon. J Trace Elem Med Biol. 2014;28(4):379–382. PMID:25081495
• Jugdaohsingh R et al. Physiological silicon incorporation into bone mineral requires orthosilicic acid metabolism to SiO44−. Sci Rep. 2020;10:10255. PMC7328383
• Erez A et al. Argininosuccinate synthase: at the center of arginine metabolism. Nat Chem Biol. 2011;7(7):462–464. PMC3074183
• Tóth A et al. L-Arginine-Nitric Oxide-Asymmetric Dimethylarginine Pathway and the Coronary Circulation. Front Pharmacol. 2020;11:569914. PMC7550781
• Buszewska-Forajta M et al. L-Arginine and Nitric Oxide in Vascular Regulation. Nutrients. 2025;17(4):665. PMC11858268
• US Patent 5,707,970: Arginine silicate complex and use thereof. USPTO.
• US Patent 6,344,444: Arginine-silicate-inositol complex and use thereof. USPTO.
• Application for the Approval of the Use of Inositol-Stabilized Arginine Silicate (ASI). UK Advisory Committee on Novel Foods and Processes (ACNFP). 2016.
• Hewlings S, Kalman D. Inositol-Stabilized Arginine Silicate: A Novel Nitric Oxide-Boosting Ingredient for Sports Nutrition and Improved Cognition. In: Nutrition and Enhanced Sports Performance (2nd ed.). Academic Press/Elsevier. 2019.